Across TCGA pan-cancer cohorts, HPR Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HPR data layer compared with 23 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HPR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HPR expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
HNSC, UCEC, and SKCM are the cancer types where HPR Mutation most reproducibly stratifies survival.